OBJECTIVE: Chronic hepatitis C affects 200 million people worldwide and is a leading cause of death from liver disease. Effective treatment is available but can be difficult to access for uninsured, urban patients. National organizations have called for improving access to hepatitis C care in these groups. We present an innovative model for expanding access to hepatitis C care for urban, underserved patients (The Grady Liver Clinic, Grady Memorial Hospital, Atlanta, Georgia). The liver clinic provides hepatitis C care by general internists in the primary care setting. METHODS: We performed a retrospective chart review of all liver clinic patients (n=807) who presented in the first 5 years of the clinic's operation. Measures included patients' demographic and hepatitis C-related characteristics; prevalence of medical, psychiatric, and substance abuse comorbidities; and treatment status. RESULTS: The liver clinic population is primarily black (76%) and uninsured (59%). Patients had difficult-to-treat characteristics, including genotype 1 hepatitis C (90%), advanced liver fibrosis (28%), and high viral loads. Sixty-seven percent had comorbid medical conditions, and 40% had psychiatric disease. Fourteen percent of patients were treated for hepatitis C during the study period. CONCLUSION: The liver clinic has proven to be a successful model for improving access to hepatitis C care for urban, underserved patients. Despite having significant hepatic disease and medical and psychiatric comorbidities, patients in the liver clinic can be successfully maintained in care and initiated on hepatitis C treatment by general internists in a primary care setting.
OBJECTIVE:Chronic hepatitis C affects 200 million people worldwide and is a leading cause of death from liver disease. Effective treatment is available but can be difficult to access for uninsured, urban patients. National organizations have called for improving access to hepatitis C care in these groups. We present an innovative model for expanding access to hepatitis C care for urban, underserved patients (The Grady Liver Clinic, Grady Memorial Hospital, Atlanta, Georgia). The liver clinic provides hepatitis C care by general internists in the primary care setting. METHODS: We performed a retrospective chart review of all liver clinic patients (n=807) who presented in the first 5 years of the clinic's operation. Measures included patients' demographic and hepatitis C-related characteristics; prevalence of medical, psychiatric, and substance abuse comorbidities; and treatment status. RESULTS: The liver clinic population is primarily black (76%) and uninsured (59%). Patients had difficult-to-treat characteristics, including genotype 1 hepatitis C (90%), advanced liver fibrosis (28%), and high viral loads. Sixty-seven percent had comorbid medical conditions, and 40% had psychiatric disease. Fourteen percent of patients were treated for hepatitis C during the study period. CONCLUSION: The liver clinic has proven to be a successful model for improving access to hepatitis C care for urban, underserved patients. Despite having significant hepatic disease and medical and psychiatric comorbidities, patients in the liver clinic can be successfully maintained in care and initiated on hepatitis C treatment by general internists in a primary care setting.
Authors: Lesley S Miller; Francois Rollin; Shelly-Ann Fluker; Kristina L Lundberg; Brandi Park; Kristi Quairoli; Nyiramugisha K Niyibizi; Anne C Spaulding Journal: Public Health Rep Date: 2016 May-Jun Impact factor: 2.792
Authors: Karen E Lasser; Alexandra Heinz; Leandra Battisti; Alexandria Akoumianakis; Ve Truong; Judith Tsui; Glorimar Ruiz; Jeffrey H Samet Journal: Ann Fam Med Date: 2017-05 Impact factor: 5.166
Authors: Anne C Spaulding; Akshay Sharma; Lauren C Messina; Maria Zlotorzynska; Lesley Miller; Ingrid A Binswanger Journal: Am J Public Health Date: 2015-03-19 Impact factor: 9.308
Authors: Sarah C Dupont; Shelly-Ann Fluker; Kristi M Quairoli; Cameron Body; Ike Okosun; Jennifer Lom; Lesley S Miller Journal: Public Health Rep Date: 2019-11-22 Impact factor: 2.792
Authors: N H Afdhal; S Zeuzem; R T Schooley; D L Thomas; J W Ward; A H Litwin; H Razavi; L Castera; T Poynard; A Muir; S H Mehta; L Dee; C Graham; D R Church; A H Talal; M S Sulkowski; I M Jacobson Journal: J Viral Hepat Date: 2013-11 Impact factor: 3.728